Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 3 Lung Neoplasms 2 Colorectal Neoplasms 2 Breast Neoplasms 2 Rectal Neoplasms 1 Pleural Effusion 1 Neuroendocrine Tumors 1 Neoplasm Metastasis 1 Insulin-Like Growth Factor I, Resistance To 1 Adenocarcinoma 1

Interventions

Oxaliplatin 146 Fluorouracil 137 Capecitabine 122 Leucovorin 106 Irinotecan 85 Radiotherapy 67 Bevacizumab 64 Cetuximab 46 Folfox protocol 28 Surgical Procedures, Operative 23 Radiation 23 Drug Therapy 22 Panitumumab 19 XELOX 18 Chemotherapy, Adjuvant 15 Neoadjuvant Therapy 14 Radiotherapy, Intensity-Modulated 13 Chemoradiotherapy 13 Magnetic Resonance Spectroscopy 11 regorafenib 10 Nivolumab 10 Floxuridine 10 sintilimab 8 raltitrexed 8 Specimen Handling 8 IFL protocol 8 Celecoxib 8 Biopsy 8 trifluridine tipiracil drug combination 7 tislelizumab 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Rectal Neoplasms × dalotuzumab × Clear all

NCT01609231 2020-05-04

MK-0646-025

Merck Sharp & Dohme LLC

Phase 2 Terminated

11 enrolled 8 charts

Gastrointestinal

Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡